Landscape Capital Management L.L.C. Sells 8,737 Shares of Guardant Health, Inc. (NASDAQ:GH)

Landscape Capital Management L.L.C. decreased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 27.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,711 shares of the company’s stock after selling 8,737 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Guardant Health were worth $694,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health in the 4th quarter valued at $43,000. Kimelman & Baird LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at $58,000. Quantbot Technologies LP bought a new stake in shares of Guardant Health during the fourth quarter worth $80,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after acquiring an additional 817 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GH. Barclays began coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective for the company. Stifel Nicolaus increased their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a report on Friday, February 21st. Morgan Stanley lifted their target price on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Guggenheim reissued a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health presently has an average rating of “Buy” and an average target price of $48.95.

Guardant Health Stock Down 3.4 %

Guardant Health stock opened at $40.58 on Monday. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89. The company has a 50 day moving average of $44.39 and a 200-day moving average of $34.96. The stock has a market capitalization of $5.01 billion, a PE ratio of -11.40 and a beta of 1.45.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.